CSI Market
Sign In | Register

X4 Pharmaceuticals Inc (XFOR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access XFOR quarterly Cash Flow →
The data below summarizes X4 Pharmaceuticals Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-79.20
Depreciation & amortization1.28
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.66
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation4.30
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Non Cash Interest Expense0.87
Adjustment Of Non Cash Rent Expense-
Derivative Gain Loss On Derivative Net-
Increase Decrease In Grant And Incentive Receivables-
Gain Loss On Preferred Stock Repurchase Liability-
Increase Decrease In Lease Liabilities-1.74
Change In Fair Value Of Convertible Preferred Stock Warrant Liability-12.78
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.50
Increase (Decrease) in Accounts Payable-2.98
Increase (Decrease) in Accrued Liabilities-2.03
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets4.25
Other Working Capital0.00
Other Noncash Income (Expense)-0.16
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.74
Discontinued operations0.00
Net Cash flow from Operating Activities-85.62
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities74.54
Payments to Acquire Marketable Securities-63.39
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-3.00
Discontinued operations0.00
Net Cash Flow from Investing Activities8.15
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock238.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments Of Issuance Costs Of Convertible Promissory Notes-
Proceeds From Issuance Of Loans Payable-
Payments Of Issuance Costs Of Redeemable Convertible Preferred Stock-
Sale Of Common Stock Pre Funded Warrants And Class A Warrants Net Of Issuance Costs-
Proceeds From Exercise Of Stock Options And Warrants-
Proceeds From Issuance Or Sale Of Equity Net Of Issuance Costs-
Proceeds From Borrowings Under Loan And Security Agreements Net Of Issuance Costs-
Issuance Costs Related To Sale Of Warrants And Fees Paid For Amendments To Loan And Security Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities238.63
Effect of exchange rate on cash flow0.21
Discontinued operations0.00
Free Cash Flow-85.62
Total Cash Flow161.38
4 historic quarters locked

Sign in to unlock the full X4 Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About X4 Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001501697-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document